Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?

Basit Öğe Kaydı
dc.authorscopusid6701356820
dc.authorscopusid55750238100
dc.authorscopusid26027024900
dc.authorscopusid6507331366
dc.authorscopusid8526920700
dc.authorscopusid55664567200
dc.authorscopusid6507778424
dc.contributor.authorSayiner, Abdullah
dc.contributor.authorErdem, Huseyin Aytac
dc.contributor.authorEkren, Pervin Korkmaz
dc.contributor.authorTasbakan, Sezai
dc.contributor.authorBasoglu, Ozen K.
dc.contributor.authorTasbakan, Meltem Isikgoz
dc.contributor.authorYamazhan, Tansu
dc.date.accessioned2023-01-12T20:15:59Z
dc.date.available2023-01-12T20:15:59Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractIntroduction: Early experience with favipiravir in the treatment of COVID-19 is promising, but no clinical data have been published in medical journals. This study aimed to review the experience with favipiravir treatment for COVID-19 pneumonia and to examine whether there are any predictors of treatment response. Methodology: Fifty-six patients with severe or progressive pneumonia associated with COVID-19 who were treated with favipiravir monotherapy for at least five days were included in this retrospective study. Treatment response was defined as clinical recovery without any need for admission into the intensive care unit and/or anti-cytokine therapy. The demographic, clinical, laboratory and radiographic features of the patients were compared between favipiravir-responders and non-responders. Results: Of the 56 patients, 34 patients (60.7%) responded to treatment and recovered. There was no difference in the demographic, clinical, and radiographic findings between the responders and non-responders. The inflammatory biomarkers were also similar except for the CRP levels on the day favipiravir was started [74 (36-111) vs. 118.5 (46.5-203) mg/L, respectively, p = 0.043]. There was also a significant difference in the median time to defervescence [1 (1-2) vs. 3.5 (1.75-9.25) days, respectively]. Of clinical interest, 27 (79.4%) and 31 (91.2%) of the responders became afebrile within two and four days, respectively. The response rate was lower in patients who presented severe pneumonia associated with respiratory failure. Conclusions: Patients with non-severe pneumonia at admission and whose fever resolved within two days of treatment are more likely to improve with favipiravir.en_US
dc.identifier.doi10.3855/jidc.14033
dc.identifier.endpage426en_US
dc.identifier.issn1972-2680
dc.identifier.issue3en_US
dc.identifier.pmid35404846en_US
dc.identifier.scopus2-s2.0-85130594747en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage422en_US
dc.identifier.urihttps://doi.org/10.3855/jidc.14033
dc.identifier.urihttps://hdl.handle.net/11454/78623
dc.identifier.volume16en_US
dc.identifier.wosWOS:000786595400005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJ Infection Developing Countriesen_US
dc.relation.ispartofJournal of Infection in Developing Countriesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjecttreatmenten_US
dc.subjectfavipiraviren_US
dc.titleFavipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu